Data Insights

Afamitresgene autoleucel by Adaptimmune Therapeutics for Peripheral Nerve Sheath Tumor (Neurofibrosarcoma): Likelihood of Approval

Afamitresgene autoleucel is under clinical development by Adaptimmune Therapeutics and currently in Phase II for Peripheral Nerve Sheath Tumor (Neurofibrosarcoma)....

Likelihood of Approval and Phase Transition Success Rate Model - Afamitresgene Autoleucel in Peripheral Nerve Sheath Tumor (Neurofibrosarcoma)

Data Insights

Afamitresgene autoleucel by Adaptimmune Therapeutics for Neuroblastoma: Likelihood of Approval

Afamitresgene autoleucel is under clinical development by Adaptimmune Therapeutics and currently in Phase II for Neuroblastoma. According to GlobalData, Phase...

Likelihood of Approval and Phase Transition Success Rate Model - Afamitresgene Autoleucel in Neuroblastoma

Data Insights

Afamitresgene autoleucel by Adaptimmune Therapeutics for Osteosarcoma: Likelihood of Approval

Afamitresgene autoleucel is under clinical development by Adaptimmune Therapeutics and currently in Phase II for Osteosarcoma. According to GlobalData, Phase...

Likelihood of Approval and Phase Transition Success Rate Model - Afamitresgene Autoleucel in Osteosarcoma

Data Insights

Afamitresgene autoleucel by Adaptimmune Therapeutics for Round Cell Liposarcoma: Likelihood of Approval

Afamitresgene autoleucel is under clinical development by Adaptimmune Therapeutics and currently in Phase II for Round Cell Liposarcoma. According to...

Data Insights

Afamitresgene autoleucel by Adaptimmune Therapeutics for Metastatic Transitional (Urothelial) Tract Cancer: Likelihood of Approval

Afamitresgene autoleucel is under clinical development by Adaptimmune Therapeutics and currently in Phase I for Metastatic Transitional (Urothelial) Tract Cancer....

Data Insights

Afamitresgene autoleucel by Adaptimmune Therapeutics for Myxoid Liposarcoma: Likelihood of Approval

Afamitresgene autoleucel is under clinical development by Adaptimmune Therapeutics and currently in Phase II for Myxoid Liposarcoma. According to GlobalData,...

Data Insights

Afamitresgene autoleucel by Adaptimmune Therapeutics for Synovial Sarcoma: Likelihood of Approval

Afamitresgene autoleucel is under clinical development by Adaptimmune Therapeutics and currently in Pre-Registration for Synovial Sarcoma. According to GlobalData, Pre-Registration...